📊 CCCC Key Takeaways
Investment Thesis
C4 Therapeutics is a pre-revenue clinical-stage biotech company with significant fundamental challenges. Despite having a strong balance sheet with $74.6M in cash and no debt, the company is burning cash at an unsustainable rate of $99.3M annually in free cash flow, with operating losses exceeding $115M against minimal $35.9M revenue. At current burn rates, the company has approximately 9 months of cash runway, creating imminent financing risk regardless of clinical progress.
CCCC Strengths
- Strong balance sheet with $74.6M cash and zero long-term debt
- Excellent liquidity position with 7.81x current ratio
- Modest revenue of $35.9M suggests early commercialization has begun
CCCC Risks
- Severe cash burn of $99.3M annually with only ~9 months of runway at current rates
- Operating losses of $115.2M on $35.9M revenue indicating business model not yet sustainable
- Net losses of $105M with -292.1% net margin indicating company is far from profitability
- Dilutive financing will likely be required within 12 months, materially impacting shareholders
Key Metrics to Watch
- Quarterly cash burn rate and cash runway remaining
- Revenue growth trajectory and path to gross profitability
- Operating expense control and progress toward cash flow breakeven
- Clinical trial progress and probability of regulatory approval for pipeline candidates
CCCC Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 7.81x current ratio provides a solid financial cushion.
CCCC Profitability Ratios
CCCC vs Healthcare Sector
How C4 Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CCCC Balance Sheet & Liquidity
CCCC 5-Year Financial Trend
5-Year Trend Summary: C4 Therapeutics, Inc.'s revenue has declined by 21% over the 5-year period, indicating business contraction. The most recent EPS of $-1.52 indicates the company is currently unprofitable.
CCCC Growth Metrics (YoY)
CCCC Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $11.2M | -$17.7M | $-0.35 |
| Q2 2025 | $6.5M | -$17.7M | $-0.26 |
| Q1 2025 | $3.0M | -$26.3M | $-0.37 |
| Q1 2023 | $2.7M | -$17.7M | $-0.26 |
| Q3 2022 | $6.8M | -$21.0M | $-0.51 |
| Q2 2022 | $9.8M | -$21.0M | $-0.51 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CCCC Capital Allocation
CCCC SEC Filings
Access official SEC EDGAR filings for C4 Therapeutics, Inc. (CIK: 0001662579)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CCCC
What is the AI rating for CCCC?
C4 Therapeutics, Inc. (CCCC) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CCCC's key strengths?
Strong balance sheet with $74.6M cash and zero long-term debt. Excellent liquidity position with 7.81x current ratio.
What are the risks of investing in CCCC?
Severe cash burn of $99.3M annually with only ~9 months of runway at current rates. Operating losses of $115.2M on $35.9M revenue indicating business model not yet sustainable.
What is CCCC's revenue and growth?
C4 Therapeutics, Inc. reported revenue of $35.9M.
Does CCCC pay dividends?
C4 Therapeutics, Inc. does not currently pay dividends.
Where can I find CCCC SEC filings?
Official SEC filings for C4 Therapeutics, Inc. (CIK: 0001662579) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CCCC's EPS?
C4 Therapeutics, Inc. has a diluted EPS of $-1.27.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.